Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
Projects that will be considered for Pfizer support will focus on:
o Increasing the understanding of the relatively poor prognosis of BRAF-mutant mCRC compared to non-BRAF-mutant mCRC1 ,
o Improving the integration of biomarker testing results into treatment of patients with mCRC, and,
o Increasing the understanding of mCRC treatment outcomes and side effect management.
Grant Application due date: 09 April 2021
Geographic Scope: United States and Canada
The following may apply: medical and/or nursing professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement. If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project. For projects offering continuing education credit, the requesting organization must be accredited.
Individual projects requesting up to $200,000 will be considered for multi-faceted projects with a broad reach; however, projects requesting smaller amounts are highly encouraged